Atrium Therapeutics Launches with $270 Million to Advance RNA Medicines for Rare Genetic Cardiomyopathies

Newly independent, publicly traded company aims to transform care for people living with severe, life-threatening genetic heart conditions

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

Atrium Therapeutics, Inc. launched today as a newly independent, publicly traded company dedicated to delivering RNA therapeutics directly to the heart to transform care for people living with rare, life-threatening genetic cardiomyopathies. The company was established in connection with Avidity Biosciences, Inc.'s acquisition by Novartis AG and begins operations with two precision cardiology candidates, two undisclosed research targets and approximately $270 million in cash and cash equivalents.

Why it matters

Patients and families facing these genetically driven rare cardiomyopathies have few if any options that address the underlying cause. Atrium is positioned to advance precision medicines designed to directly target the biologic drivers of cardiac disease, helping to pave the way for a new era for RNA therapies in precision cardiology.

The details

Atrium Therapeutics' two lead development candidates are: ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy. Both conditions are severe, life-threatening, rare autosomal dominant progressive cardiomyopathies with no approved therapies to treat the underlying cause of disease. Atrium expects to file INDs for both programs in 2026 and 2027, respectively, and advance them into clinical trials pending supportive Phase 1 results.

  • Atrium Therapeutics was established in connection with Avidity Biosciences, Inc.'s acquisition by Novartis AG.
  • Atrium expects to file an IND for ATR 1072 (PRKAG2 syndrome) in the second half of 2026.
  • Atrium plans to initiate IND-enabling preclinical studies for ATR 1086 (PLN cardiomyopathy) in 2026, targeting an IND submission in 2027.

The players

Atrium Therapeutics, Inc.

A newly independent, publicly traded company dedicated to delivering RNA therapeutics directly to the heart to transform care for people living with rare, life-threatening genetic cardiomyopathies.

Kathleen Gallagher

President and Chief Executive Officer of Atrium Therapeutics.

Sarah Boyce

Chair of Atrium Therapeutics' board of directors and former CEO of Avidity Biosciences, Inc.

PRKAG2 syndrome

A rare, autosomal dominant, early-onset cardiomyopathy caused by mutations in the PRKAG2 gene, with 1,000 – 2,000 people affected in the US.

PLN cardiomyopathy

A rare autosomal dominant, progressive cardiac disease caused by mutations in PLN, a key regulator of SERCA2a calcium pump, with 2,000 – 4,000 people affected in the US.

Got photos? Submit your photos here. ›

What they’re saying

“The launch of Atrium Therapeutics marks an important milestone for people living with genetic cardiomyopathies. Patients and families facing these genetically driven rare cardiomyopathies have few if any options that address the underlying cause. Building on Avidity's pioneering work in targeted RNA delivery, Atrium is positioned to advance precision medicines designed to directly target the biologic drivers of cardiac disease. Atrium has the opportunity to help pave the way for a new era for RNA therapies in precision cardiology.”

— Kathleen Gallagher, President and CEO of Atrium Therapeutics

“As Atrium Therapeutics embarks on a new chapter today, I am incredibly proud of the team's commitment to advancing groundbreaking science for people with genetically driven cardiomyopathies. Precision cardiology is an area of immense opportunity, and I am confident the Atrium Therapeutics team's experiences in rare disease, drug development and RNA therapeutics and patient-focused approach will urgently move its pipeline forward.”

— Sarah Boyce, Chair of Atrium Therapeutics' board of directors and former CEO of Avidity Biosciences

What’s next

Pending supportive Phase 1 trial results, Atrium Therapeutics anticipates advancing both ATR 1072 and ATR 1086 programs into clinical trials, while continuing to expand its additional precision cardiology pipeline and develop its next-generation RNA delivery platform.

The takeaway

Atrium Therapeutics' launch represents a significant step forward in addressing the unmet needs of patients and families facing rare, genetically driven cardiomyopathies, leveraging a pioneering approach to targeted RNA delivery to the heart that could transform the standard of care in precision cardiology.